A second update from Pathos AI’s deal activity outlined the company’s access to a TROP2/HER3 bispecific ADC through Alphamab licensing. The arrangement provides Pathos with rights to develop, manufacture, and commercialize JSKN016 outside mainland China and certain other territories where Alphamab retains exclusivity. The ADC is being evaluated across multiple solid tumors, including breast, lung, gastric, and colorectal cancer, positioning the asset for broader registrational pathways depending on trial outcomes. Pathos also emphasized continued pipeline building through additional strategic partnerships. The announcement reinforces how the ADC landscape remains active for licensing—especially for bispecific targets tied to tumor antigen expression patterns.